Tag: IR

Palo Alto, California, June 02, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB, MOBBW) (“Mobilicom” or the “Company”), a provider of cybersecurity and robust solutions for drones and robotics, today announced that Oren Elkayam, Chief Executive Officer and Founder, will participate in a fireside chat at the Jefferies 2026 Defense Technology Virtual Summit.

GARDENA, California, June 02, 2026 (GLOBE NEWSWIRE) -- Polar Power, Inc. (“Polar Power” or the “Company”) (NASDAQ: POLA), a global provider of prime, backup and solar hybrid DC power solutions, today highlighted its financial results for its first quarter ended March 31, 2026, which the Company disclosed by its quarterly report on Form 10-Q with the Securities and Exchange Commission on May 20, 2026, and its recent operational progress. The quarter reflected substantial year-over-year gains in gross margin, operating results, and balance sheet strength, supported by a $3.7 million sales order backlog as of March 31, 2026.

SAN JUAN CAPISTRANO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the real estate and operations of “Woodland Health and Rehabilitation,” a 62-bed skilled nursing facility located in Mount Pleasant, Iowa. The real estate was acquired by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign’s captive real estate company, and the facility is operated by an Ensign-affiliated tenant. The acquisition was effective as of June 1, 2026.

LONDON, June 02, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD), a global HealthTech company advancing wellness through evidence-based, personalized nutrition solutions, is pleased to provide investors with further insight into the progression of its AI-powered agentic infrastructure across both investor and consumer-facing operations following completion of its recently announced Australian wellness platform transaction.

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　 announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Targeted to Begin Generating Revenue Between Late 2028 and Mid-2029 Following Siemens Restoration at U.S. Facilities.